Test of a Preventive Effect of a Deodorant Device Against Respiratory Infections (Cleverin)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00969800|
Recruitment Status : Unknown
Verified February 2010 by Taiko Pharmaceutical Co., Ltd..
Recruitment status was: Active, not recruiting
First Posted : September 1, 2009
Last Update Posted : February 4, 2010
|Condition or disease||Intervention/treatment||Phase|
|Respiratory Infection||Device: Cleverin Gel Device: Inactive Cleverin Gel||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1469 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Double-blind Sham Device-controlled Multi-center Crossover Trial of Chlorine Dioxide Gas on the Protective Effect Against Respiratory Infections|
|Study Start Date :||October 2009|
|Estimated Primary Completion Date :||March 2010|
|Estimated Study Completion Date :||April 2010|
Experimental: Active Cleverin Gel
Active Cleverin Gel, which generates chlorine dioxide gas, is placed in a room of subject.
Device: Cleverin Gel
Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
Other Name: ClO2 gas generator
Sham Comparator: Inactive Cleverin Gel
Inactive Cleverin Gel is placed in a room of subject. It does not generate chlorine dioxide gas.
Device: Inactive Cleverin Gel
Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
Other Name: sham ClO2 gas generator
- The number of incidence of respiratory infections [ Time Frame: Four months ]
- The incidence of adverse effects [ Time Frame: Four months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00969800
|Reifuen Nursing Home|
|Osaka, Japan, 558-0054|
|Principal Investigator:||Norio Ogata, MD, PhD||Taiko Pharmaceutical Co., Ltd.|